Recently, Py et al. reported the efficacy of trametinib (a MEK inhibitor) in a patient with an immunotherapy-refractory melanoma with BRAF/NRAS wild-types and mutations in NF1 and PTPN11 [118]. This evidence concerns the gene BRAF and melanoma.